Kromek

Sedgefield's Kromek Group plc, a leader in radiation and bio-detection technologies, has secured a contract worth up to $2.9 million over the next two years with a US federal entity.

This contract reaffirms the trust and satisfaction that an existing customer has in Kromek's capabilities, focusing on the supply of nuclear security products. Under the terms of the contract, Kromek will provide its advanced, wearable radiation detectors—the D5 RIID, D3M, and D3S-ID. The company has received an initial order worth $358,000 for immediate delivery, with the possibility of additional orders up to $2.5 million over the next 24 months.

Arnab Basu, CEO of Kromek, said: “We are pleased to have received this new contract, which reflects the strength of our longstanding business relationships and the quality of our nuclear security offering. We are continuing to experience excellent momentum in CBRN Detection as the threats to public security persist across the globe. We believe our products provide best-in-class capability to manage these threats and, consequently, we expect to receive further nuclear security orders in the near term.”

Kromek remains a key part of the Sedgefield community, based at the NETPark Technology park, demonstrating the region’s capability as a center for technological innovation and excellence in security solutions.

ENDS

CONTACT: JOSH MASON 01325 363436

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer’s, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek’s compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of ‘dirty bombs’.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol ‘KMK’.

Further information is available at www.kromek.com.